Previous close | 83.59 |
Open | 84.92 |
Bid | 0.00 x 1400 |
Ask | 0.00 x 900 |
Day's range | 82.92 - 86.55 |
52-week range | 50.50 - 100.00 |
Volume | |
Avg. volume | 587,517 |
Market cap | 4.441B |
Beta (5Y monthly) | 1.45 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.01 |
Earnings date | 07 Nov 2022 - 11 Nov 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 102.50 |
Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.
Joining me on today's call are Bill Hoffman, president and chief executive officer; Drew Hykes, chief operating officer; and Mitch Hill, chief financial officer. This call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 17.39% and 5.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?